Effect of rituximab on a salivary gland ultrasound score in primary Sjögren’s syndrome: Results of the TRACTISS randomised double-blind multicentre substudy
Annals of Rheumatic Diseases Jan 05, 2018
Fisher BA, et al. - Researchers carried out a multicentre, multiobserver phase III trial substudy to compare the impacts of rituximab vs placebo on salivary gland ultrasound (SGUS) in primary Sjögren’s syndrome (PSS). They found that rituximab vs placebo resulted in statistically significant improvement in total ultrasound score in this patient population.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
